OR WAIT null SECS
Arthur L. Burnett, II, MD, MBA, discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED as well as how the new guideline addresses novel treatments that are not currently FDA approved.
A new AUA clinical guideline on the diagnosis and treatment of erectile dysfunction is rigorous and evidence based while representing evolution of the field since the AUA last published a guideline on ED in 2005, says Arthur L. Burnett, II, MD, MBA, chair of the guideline development panel.
“We have actually decided to move forward with a new paradigm as well that allows us to move all the therapies forward in a way that we think is most useful and appropriate for patients,” said Dr. Burnett, of Johns Hopkins University School of Medicine in Baltimore.
In an interview at the AUA annual meeting, Dr. Burnett discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED, how the new guideline addresses novel treatments that are not currently FDA approved, and the shift from a process-of-care model to a shared decision-making model.
Dr. Burnett is a consultant/adviser to Astellas, Genomic Health, and Lilly, and conducts scientific studies/trials for Endo Pharmaceuticals, Pfizer, the National Institutes of Health, American Medical Systems/Boston Scientific, Coloplast, Reflexonic LLC, Medispec, Lilly, and Acorda Therapeutics.